OMOmar G. Mustafa

Omar G. Mustafa

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Omar G. Mustafa has a total of 142 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • An International Position Statement on Practical Approaches for Inpatient Continuous Glucose Monitoring, Insulin Pumps, and Automated Insulin Delivery Systems in Adults

    by Mikkel T. Olsen, Elias K. Spanakis, Hood Thabit, Ketan Dhatariya, Omar G. Mustafa, Parizad Avari, Alistair N. Lumb, Katheleen Dungan, Athena Philis-Tsimikas, Kristen Kulasa, et al.

    There is an urgent and unmet need for a practical clinical guideline addressing the use of continuous glucose monitoring (CGM), insulin pumps, and automated insulin delivery (AID) systems in hospital settings. The goal with this position statement is to facilitate effective and safe use of these devices to improve glycemic management, enhance outcomes, and contribute to standardization efforts in initiating or continuing the use of these devices in hospitals for non–critically ill hospitalized adults. The topics covered include selection criteria for management with diabetes technologies, CGM-derived glycemic metrics and goals for adults with diabetes, insulin titration and administration guidelines, perioperative care, CGM alarm settings for hypoglycemia and hyperglycemia, clinical staff training and workflows, integration of device data with the electronic health record, imaging tests considerations, and discharge planning.


  • Open Access

    An international position statement on practical approaches for inpatient continuous glucose monitoring, insulin pumps and automated insulin delivery systems in adults

    by Mikkel T. Olsen, Elias K. Spanakis, Hood Thabit, Ketan Dhatariya, Omar G. Mustafa, Parizad Avari, Alistair N. Lumb, Katheleen Dungan, Athena Philis-Tsimikas, Kristen Kulasa, et al.

    There is an urgent and unmet need for a practical clinical guideline addressing the use of continuous glucose monitoring (CGM), insulin pumps and automated insulin delivery (AID) systems in hospital settings. The goal with this position statement is to facilitate effective and safe use of these devices to improve glycaemic management, enhance outcomes and contribute to standardisation efforts in initiating or continuing the use of these devices in hospitals for non-critically ill hospitalised adults. The topics covered include selection criteria for management with diabetes technologies, CGM-derived glycaemic metrics and goals for adults with diabetes, insulin titration and administration guidelines, perioperative care, CGM alarm settings for hypoglycaemia and hyperglycaemia, clinical staff training and workflows, integration of device data with the electronic health record, imaging tests considerations and discharge planning. Graphical Abstract

  • Open Access

    Diabetes management in people undergoing metabolic‐bariatric surgery: A guideline from the Joint British Diabetes Societies for Inpatient Care ( JBDS ‐ IP ) Group

    by Jeffrey W. Stephens, Ketan Dhatariya, Andrew J. Beamish, Dimitri J. Pournaras, Alexander D. Miras, Nader Raafat, Georgia Noble‐Bell, Rachel Cadwallader Buckland, Omar G. Mustafa

    The global prevalence of obesity and diabetes continues to rise, with metabolic‐bariatric surgery recognised as an effective intervention for obesity and type 2 diabetes, offering potential for type 2 diabetes remission and improved glycaemic control. This guideline, developed by the Joint British Diabetes Societies for Inpatient Care (JBDS‐IP), provides recommendations for the management of diabetes in individuals undergoing metabolic‐bariatric surgery. It emphasises the importance of multidisciplinary care and individualised treatment plans to optimise outcomes. Key recommendations include pre‐operative glycaemic optimisation, targeting HbA1c <69 mmol/mol (<8.5%) where safe to do so, prevention of hypoglycaemia throughout all phases of care and providing a framework for medication adjustments during the liver reduction diet (LRD), peri‐operative and post‐operative phases. For type 2 diabetes, oral and non‐insulin therapies such as metformin, DPP4 inhibitors and GLP‐1 based therapies may be continued during LRD, while sulfonylureas, meglitinides and SGLT2 inhibitors should be discontinued to reduce the risk of hypoglycaemia. For those with type 2 diabetes on insulin, doses should be reduced by 35%–50% during LRD and adjusted post‐operatively based on individual glycaemic control. To prevent diabetic ketoacidosis (DKA) in those with type 1 diabetes, insulin must never be stopped and careful planning with diabetes teams is essential. Post‐operatively, regular glucose monitoring, hypoglycaemia surveillance, medication adjustments, and follow‐up with diabetes specialists are recommended. This document serves as a guide for clinicians and service commissioners, aiming to improve inpatient diabetes care and outcomes for individuals undergoing metabolic‐bariatric surgery.


  • Open Access

    Peri‐operative management of diabetes mellitus: a multidisciplinary consensus statement from the Association of Anaesthetists and the Joint British Diabetes Societies for Inpatient Care group

    by Nicholas A. Levy, Kariem El‐Boghdadly, Dileep N. Lobo, Daniel J. Stubbs, Parizad Avari, Donal Buggy, Claire Frank, Kim Howson, Jinty Moffett, Emma Morris, et al.

    Summary: Introduction: Surgery in patients with diabetes mellitus is associated with increased morbidity and mortality compared with those who do not have diabetes mellitus. This is likely multifactorial and could be attributed to organisational issues; dysglycaemia; hospital‐acquired diabetic ketoacidosis; errors with insulin prescribing and administration; issues with fluids and electrolytes; and systemic and surgical site infections. There was a need to update guidance for the peri‐operative management of diabetes mellitus given improvements in our understanding, introduction of novel drugs and development of wearable technologies. Methods: This was a multidisciplinary consensus statement with a diverse authorship group, including diabetologists; anaesthetists; surgeons; pharmacists; surgical diabetes inpatient specialist nurses; and patients with lived experience. We undertook a directed literature search and a three‐round Delphi process to develop, refine and agree recommendations. Results: Following three rounds, 38 recommendations were included, spanning all phases of the peri‐operative pathway. Recommendations were made for organisations and general principles for the management of patients with diabetes, aiming to improve pathways, implement protocols and support training. We prioritise individualised care plans, encourage clinical judgement regarding proceeding with surgery with out‐of‐range HbA1c concentrations and recommend ensuring appropriate insulin regimens are prescribed and administered. We also provide guidance for capillary blood glucose and ketone monitoring and management; safe handovers of care; and multidisciplinary care plans for the peri‐operative use of wearables. Discussion: This consensus statement provides principles to be applied throughout the entire peri‐operative pathway by healthcare professionals, institutions and patients. It is hoped that the implementation of these key recommendations will improve experience and outcomes for patients with diabetes mellitus having surgery.


  • Open Access

    Preliminary Study on Circulating REG3α and Its Associations with Vitamin D Supplementation and Inflammatory Biomarkers in Adults with Overweight and Obesity

    by Theocharis Koufakis, Dimitrios Kouroupis, Areti Kourti, Paraskevi Karalazou, Katerina Thisiadou, Ioannis Georgiadis, Omar Mustafa, Giuseppe Maltese, Luca Busetto, Djordje S. Popovic, et al.

    Objective: Obesity is characterized by chronic inflammation and gut dysbiosis, yet circulating markers reflecting intestinal immune activation remain limited. Regenerating islet-derived protein 3 alpha (REG3α), an antimicrobial peptide secreted by intestinal Paneth cells, plays a pivotal role in mucosal defense and mirrors microbial–epithelial interactions. In this cross-sectional study, we aimed to examine circulating REG3α levels in infection-free adults with obesity, overweight, and normal weight, and to explore their associations with vitamin D supplementation and biomarkers of inflammation and dysbiosis. Methods: Sixty-nine participants were stratified into control, overweight, and obesity groups. Serum REG3α, interleukin-6 (IL-6), β-defensin-2, high-sensitivity c-reactive protein, ferritin, and presepsin were assessed. Vitamin D status and supplementation history were recorded. Multivariable linear regression, principal component analysis (PCA), and bootstrap mediation models were applied to explore associations and potential indirect effects. Results: REG3α concentrations were higher in overweight and obesity compared to controls (646 ± 217 vs. 521 ± 311 ng/mL); however, the difference was not significant (p = 0.15). Vitamin D supplementation was inversely associated with REG3α (p = 0.06), and this effect appeared weaker in obesity. REG3α correlated positively with IL-6 (ρ = 0.28) and β-defensin-2 (ρ = 0.43). PCA revealed a shared inflammatory–mucosal activation component that predicted REG3α levels. Exploratory mediation suggested a partial indirect effect of vitamin D via reduced inflammatory activity. Conclusions: Circulating REG3α shows associations with indicators of inflammation and vitamin D supplementation in individuals with overweight and obesity. Although differences between groups did not reach statistical significance, the observed trends suggest possible links between mucosal immune activity and metabolic status. These exploratory results warrant validation in larger, longitudinal studies before any biomarker role can be established.


  • Open Access

    Implementation of an Electronic Clinical Decision Support System for the Early Recognition and Management of Dysglycemia in an Inpatient Mental Health Setting Using CogStack: Protocol for a Pilot Hybrid Type 3 Effectiveness-Implementation Randomized Controlled Cluster Trial

    by Dipen Patel, Yamiko Joseph Msosa, Tao Wang, Julie Williams, Omar G Mustafa, Siobhan Gee, Barbara Arroyo, Damian Larkin, Trevor Tiedt, Angus Roberts, et al.

    Background: Severe mental illnesses (SMIs), including schizophrenia, bipolar affective disorder, and major depressive disorder, are associated with an increased risk of physical health comorbidities and premature mortality from conditions including cardiovascular disease and diabetes. Digital technologies such as electronic clinical decision support systems (eCDSSs) could play a crucial role in improving the clinician-led management of conditions such as dysglycemia (deranged blood sugar levels) and associated conditions such as diabetes in people with a diagnosis of SMI in mental health settings. Objective: We have developed a real-time eCDSS using CogStack, an information retrieval and extraction platform, to automatically alert clinicians with National Health Service Trust–approved, guideline-based recommendations for dysglycemia monitoring and management in secondary mental health care. This novel system aims to improve the management of dysglycemia and associated conditions, such as diabetes, in SMI. This protocol describes a pilot study to explore the acceptability, feasibility, and evaluation of its implementation in a mental health inpatient setting. Methods: This will be a pilot hybrid type 3 effectiveness-implementation randomized controlled cluster trial in inpatient mental health wards. A ward will be the unit of recruitment, where it will be randomly allocated to receive either access to the eCDSS plus usual care or usual care alone over a 4-month period. We will measure implementation outcomes, including the feasibility and acceptability of the eCDSS to clinicians, as primary outcomes, alongside secondary outcomes relating to the process of care measures such as dysglycemia screening rates. An evaluation of other implementation outcomes relating to the eCDSS will be conducted, identifying facilitators and barriers based on established implementation science frameworks. Results: Enrollment of wards began in April 2022, after which clinical staff were recruited to take part in surveys and interviews. The intervention period of the trial began in February 2023, and subsequent data collection was completed in August 2023. Data are currently being analyzed, and results are expected to be available in June 2024. Conclusions: An eCDSS can have the potential to improve clinician-led management of dysglycemia in inpatient mental health settings. If found to be feasible and acceptable, then, in combination with the results of the implementation evaluation, the system can be refined and improved to support future successful implementation. A larger and more definitive effectiveness trial should then be conducted to assess its impact on clinical outcomes and to inform scalability and application to other conditions in wider mental health care settings. Trial Registration: ClinicalTrials.gov NCT04792268; https://clinicaltrials.gov/study/NCT04792268


  • Perioperative use of glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter 2 inhibitors for diabetes mellitus

    by Ketan Dhatariya, Nicholas Levy, Kim Russon, Anil Patel, Claire Frank, Omar Mustafa, Philip Newland-Jones, Gerry Rayman, Sarah Tinsley, Jugdeep Dhesi


  • Optimal staffing for a good quality inpatient diabetes service

    by U. Dashora, D. Flanagan, G. Rayman, O. G. Mustafa, E. Walden, K. Dhatariya, The Joint British Diabetes Societies

    Introduction: Increasing numbers of people admitted to hospital have diabetes and need specialist support. To date, there is no mechanism which can help teams estimate the number of health care professionals they need to provide optimal care for people with diabetes in hospitals.Methods: The Joint British Diabetes Societies (JBDS) for Inpatient Care Group organised a survey of specialist inpatient diabetes teams in the UK for current staffing and the perception of optimal staffing using mailing lists available through their representative organisations. The results were verified and confirmed by one‐to‐one conversations with individual respondents and discussed in multiple expert‐group meetings to agree on the results.Results: Responses were received from 17 Trusts covering 30 hospital sites. Current diabetes specialist staffing level per 100 people with diabetes in hospital (Median, IQR) for consultants was 0.24 (0.22–0.37), diabetes inpatient specialist nurses was 1.94 (1.22–2.6), dieticians was 0.00 (0.00–0.00), podiatrists was 0.19 (0.00–0.62), pharmacists was 0.00 (0.00–0.37), psychologists was 0.00 (0.00–0.00). The teams also reported that for optimal care the total staff needed for each group (Median, IQR) was much higher; consultants 0.65 (0.50–0.88), specialist nurses 3.38 (2.78–4.59), dieticians 0.48 (0.33–0.72), podiatrists, 0.93 (0.65–1.24), pharmacists, 0.65 (0.40–0.79) and psychologists 0.33 (0.27–0.58). Based on the results of the survey, the JBDS expert group produced an Excel calculator to estimate staffing needs of any hospital site in question just by populating a few of the cells.Conclusion: Current inpatient diabetes staffing is much lower than needed in most Trusts who responded to the survey. The JBDS calculator can provide an estimate of the staffing needs of any hospital.


  • Open Access

    Accreditation of the Iraqi Medical Colleges: Urgent call for action

    by Omar Mustafa, Ghanim Alsheikh

    The National Council for Accreditation of Medical Colleges (NCAMC) has made some progress towards accrediting Iraqi medical schools. However, to date, NCAMC is not internationally recognized by the World Federation for Medical Education (WFME) which fulfils the requirements of the ECFMG’s Recognized Accreditation Policy (due for initial implementation from 2024). The policy requires that a medical school must achieve a recognized accreditation status by a recognized accrediting agency that in itself is recognized and reviewed by an external quality assurance organization. When the policy is fully implemented, only medical schools accredited in line with the Recognized Accreditation Policy will satisfy the requirements of the ECFMG. Medical graduates intending to pursue work, training, registration, research, volunteering or other opportunities are required to apply for verification of their primary medical qualification (PMQ). Certification and verification of PMQ for international medical graduates (IMGs) in the United States, Australia, Canada, Ireland, New Zealand, and the United Kingdom and an increasing number of countries globally is done via the ECFMG’s online system known as Electronic Portfolio of International Credentials (EPIC). Therefore, the future of Iraqi medical schools’ education standards is at stake as they do not meet the international standards risking the future of new graduates. The Ministry of Higher Education, universities, medical colleges and the Iraqi Medical Association (IMA) need to collaborate with the NCAMC to get it recognized by the WFME in order to safeguard Iraqi medical education and the future of new doctors from 2024.


  • Open Access

    Implementation of an Electronic Clinical Decision Support System for the Early Recognition and Management of Dysglycemia in an Inpatient Mental Health Setting Using CogStack: Protocol for a Pilot Hybrid Type 3 Effectiveness-Implementation Randomized Controlled Cluster Trial (Preprint)

    by Dipen Patel, Yamiko Joseph Msosa, Tao Wang, Julie Williams, Omar G Mustafa, Siobhan Gee, Barbara Arroyo, Damian Larkin, Trevor Tiedt, Angus Roberts, et al.

    BACKGROUND Severe mental illnesses (SMIs), including schizophrenia, bipolar affective disorder, and major depressive disorder, are associated with an increased risk of physical health comorbidities and premature mortality from conditions including cardiovascular disease and diabetes. Digital technologies such as electronic clinical decision support systems (eCDSSs) could play a crucial role in improving the clinician-led management of conditions such as dysglycemia (deranged blood sugar levels) and associated conditions such as diabetes in people with a diagnosis of SMI in mental health settings. OBJECTIVE We have developed a real-time eCDSS using CogStack, an information retrieval and extraction platform, to automatically alert clinicians with National Health Service Trust–approved, guideline-based recommendations for dysglycemia monitoring and management in secondary mental health care. This novel system aims to improve the management of dysglycemia and associated conditions, such as diabetes, in SMI. This protocol describes a pilot study to explore the acceptability, feasibility, and evaluation of its implementation in a mental health inpatient setting. METHODS This will be a pilot hybrid type 3 effectiveness-implementation randomized controlled cluster trial in inpatient mental health wards. A ward will be the unit of recruitment, where it will be randomly allocated to receive either access to the eCDSS plus usual care or usual care alone over a 4-month period. We will measure implementation outcomes, including the feasibility and acceptability of the eCDSS to clinicians, as primary outcomes, alongside secondary outcomes relating to the process of care measures such as dysglycemia screening rates. An evaluation of other implementation outcomes relating to the eCDSS will be conducted, identifying facilitators and barriers based on established implementation science frameworks. RESULTS Enrollment of wards began in April 2022, after which clinical staff were recruited to take part in surveys and interviews. The intervention period of the trial began in February 2023, and subsequent data collection was completed in August 2023. Data are currently being analyzed, and results are expected to be available in June 2024. CONCLUSIONS An eCDSS can have the potential to improve clinician-led management of dysglycemia in inpatient mental health settings. If found to be feasible and acceptable, then, in combination with the results of the implementation evaluation, the system can be refined and improved to support future successful implementation. A larger and more definitive effectiveness trial should then be conducted to assess its impact on clinical outcomes and to inform scalability and application to other conditions in wider mental health care settings. CLINICALTRIAL ClinicalTrials.gov NCT04792268; https://clinicaltrials.gov/study/NCT04792268 INTERNATIONAL REGISTERED REPORT DERR1-10.2196/49548